Patents by Inventor David J. Loury

David J. Loury has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PURINONE COMPOUNDS AS KINASE INHIBITORS
    Publication number: 20160368924
    Abstract: Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. In addition, reversible inhibitors of Btk are also described. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
    Type: Application
    Filed: July 1, 2016
    Publication date: December 22, 2016
    Inventors: Wei Chen, David J. Loury, Shunqi Yan, Longcheng Wang, Leah L. Frye
  • Formulations of histone deacetylase inhibitor in combination with bendamustine and uses thereof
    Patent number: 9492423
    Abstract: Dosing regimens, methods of treatment, controlled release formulations, and combination therapies that include bendamustine, or a pharmaceutically acceptable salt thereof and an HDAC inhibitor, or a pharmaceutically acceptable salt thereof, are described.
    Type: Grant
    Filed: September 13, 2011
    Date of Patent: November 15, 2016
    Assignee: PHARMACYCLICS LLC
    Inventors: David J. Loury, Joseph J. Buggy, Tarak D. Mody, Erik J. Verner, Norbert Purro, Sriram Balasubramanian, Ioana Kloos, Stephane Depil
  • USE OF INHIBITORS OF BRUTON'S TYROSINE KINASE (BTK)
    Publication number: 20160324859
    Abstract: Disclosed herein are methods for treating a cancer comprising: a. administering a Btk inhibitor to a subject sufficient to result in an increase or appearance in the blood of a subpopulation of lymphocytes defined by immunophenotyping; b. determining the expression profile of one or more biomarkers from one or more subpopulation of lymphocytes; and c. administering a second agent based on the determined expression profile.
    Type: Application
    Filed: March 10, 2016
    Publication date: November 10, 2016
    Inventors: Joseph J. Buggy, Laurence Elias, Gwen Fyfe, Eric Hedrick, David J. Loury, Tarak D. Mody
  • Purinone compounds as kinase inhibitors
    Patent number: 9469642
    Abstract: Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. In addition, reversible inhibitors of Btk are also described. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
    Type: Grant
    Filed: January 30, 2013
    Date of Patent: October 18, 2016
    Assignee: PHARMACYCLICS LLC
    Inventors: Wei Chen, David J. Loury, Shunqi Yan, Longcheng Wang, Leah Lynn Frye
  • Formulations of histone deacetylase inhibitor and uses therof
    Patent number: 9403032
    Abstract: Dosing regimens, methods of treatment, controlled release formulations, and combination therapies that include an HDAC inhibitor, or a pharmaceutically acceptable salt thereof, are described.
    Type: Grant
    Filed: October 31, 2013
    Date of Patent: August 2, 2016
    Assignee: Pharmacyclics LLC
    Inventors: David J. Loury, Joseph J. Buggy, Tarak D. Mody, Erik J. Verner, Norbert Purro, Sriram Balasubramanian
  • Use of Inhibitors of Bruton's Tyrosine Kinase (BTK)
    Publication number: 20160175312
    Abstract: Disclosed herein are methods for treating a cancer comprising: a. administering a Btk inhibitor to a subject sufficient to result in an increase or appearance in the blood of a subpopulation of lymphocytes defined by immunophenotyping; b. determining the expression profile of one or more biomarkers from one or more subpopulation of lymphocytes; and c. administering a second agent based on the determined expression profile.
    Type: Application
    Filed: February 26, 2016
    Publication date: June 23, 2016
    Inventors: Joseph J. Buggy, Laurence Elias, Gwen Fyfe, Eric Hedrick, David J. Loury, Tarak D. Mody
  • PURINONE COMPOUNDS AS KINASE INHIBITORS
    Publication number: 20160168149
    Abstract: Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. In addition, reversible inhibitors of Btk are also described. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
    Type: Application
    Filed: June 30, 2014
    Publication date: June 16, 2016
    Inventors: Wei Chen, Zhaozhong J. Jia, David J. Loury
  • Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
    Patent number: 9273051
    Abstract: Disclosed herein are compounds of Formula (I) that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
    Type: Grant
    Filed: September 14, 2012
    Date of Patent: March 1, 2016
    Assignee: Pharmacyclics LLC
    Inventors: Wei Chen, David J. Loury
  • INHIBITORS OF BRUTON'S TYROSINE KINASE
    Publication number: 20160002225
    Abstract: Disclosed herein are compounds that inhibit Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. In addition, reversible inhibitors of Btk are also described. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
    Type: Application
    Filed: July 2, 2015
    Publication date: January 7, 2016
    Inventors: Wei CHEN, Longcheng WANG, Shunqi YAN, David J. LOURY, Zhaozhong J. JIA, Leah Lynn FRYE, Jeremy Robert GREENWOOD, Mee Yoo SHELLEY, Gordana Babic ATALLAH, Riccardo ZANALETTI, Maria Pia CATALANI, Luca Francesco RAVEGLIA
  • INHIBITORS OF BRUTON'S TYROSINE KINASE
    Publication number: 20160002241
    Abstract: Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. In addition, reversible inhibitors of Btk are also described. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
    Type: Application
    Filed: February 20, 2014
    Publication date: January 7, 2016
    Applicant: PHARMACYCLICS, LLC.
    Inventors: Wei CHEN, Shunqi YAN, David J. LOURY, Leah Lynn FRYE, Jeremy Robert GREENWOOD, Mee Yoo SHELLEY, Longcheng WANG
  • INHIBITORS OF BRUTON'S TYROSINE KINASE
    Publication number: 20150329550
    Abstract: Described herein are kinase inhibitor compounds, methods for synthesizing such inhibitors, and methods for using such inhibitors in the treatment of diseases. Further described herein are methods, assays and systems for determining an appropriate inhibitor of a protein, including a kinase.
    Type: Application
    Filed: July 28, 2015
    Publication date: November 19, 2015
    Inventors: Wei CHEN, David J. LOURY, Tarak D. MODY, Longcheng WANG
  • Inhibitors of bruton's tyrosine kinase
    Patent number: 9139591
    Abstract: Described herein are irreversible kinase inhibitor compounds exemplified by the following structure Formula (A2): methods for synthesizing such irreversible inhibitors, and methods for using such irreversible inhibitors in the treatment of a B cell proliferative disorder or a mast cell proliferative disorder.
    Type: Grant
    Filed: July 6, 2012
    Date of Patent: September 22, 2015
    Assignee: PHARMACYCLICS LLC
    Inventors: Lee Honigberg, Erik J. Verner, Joseph J. Buggy, David J. Loury, Wei Chen
  • Inhibitors of Bruton's tyrosine kinase
    Patent number: 9138436
    Abstract: Described herein are kinase inhibitor compounds, methods for synthesizing such inhibitors, and methods for using such inhibitors in the treatment of diseases. Further described herein are methods, assays and systems for determining an appropriate inhibitor of a protein, including a kinase.
    Type: Grant
    Filed: July 13, 2012
    Date of Patent: September 22, 2015
    Assignee: PHARMACYCLICS LLC
    Inventors: Wei Chen, David J. Loury, Tarak D. Mody, Longcheng Wang
  • Inhibitors of bruton's tyrosine kinase
    Patent number: 9133134
    Abstract: Described herein are kinase inhibitor compounds, methods for synthesizing such inhibitors, and methods for using such inhibitors in the treatment of diseases. Further described herein are methods, assays and systems for determining an appropriate inhibitor of a protein, including a kinase.
    Type: Grant
    Filed: May 15, 2013
    Date of Patent: September 15, 2015
    Assignee: PHARMACYCLICS LLC
    Inventors: Wei Chen, David J. Loury, Tarak D. Mody
  • Use of inhibitors of Bruton's tyrosine kinase (Btk)
    Patent number: 9125889
    Abstract: Disclosed herein are methods for treating a cancer comprising: a. administering a Btk inhibitor to a subject sufficient to result in an increase or appearance in the blood of a subpopulation of lymphocytes defined by immunophenotyping; b. determining the expression profile of one or more biomarkers from one or more subpopulation of lymphocytes; and c. administering a second agent based on the determined expression profile.
    Type: Grant
    Filed: July 31, 2014
    Date of Patent: September 8, 2015
    Assignee: Pharmacyclics, Inc.
    Inventors: Joseph J. Buggy, Laurence Elias, Gwen Fyfe, Eric Hedrick, David J. Loury, Tarak D. Mody
  • PYRROLOPYRIMIDINE COMPOUNDS AS KINASE INHIBITORS
    Publication number: 20150239897
    Abstract: Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. In addition, reversible inhibitors of Btk are also described. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
    Type: Application
    Filed: May 8, 2015
    Publication date: August 27, 2015
    Inventors: Wei CHEN, David J. LOURY, Longcheng WANG
  • Pyrrolopyrimidine compounds as kinase inhibitors
    Patent number: 9096604
    Abstract: Disclosed herein are compounds exemplified by the following structure Formula (I) that form covalent bonds with Bruton's tyrosine kinase (Btk). Also disclosed are pharmaceutical compositions that include the compounds of Formula (I). Methods of using the Btk inhibitors exemplified by the structure of Formula (I) are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
    Type: Grant
    Filed: November 15, 2013
    Date of Patent: August 4, 2015
    Assignee: PHARMACYCLICS, INC.
    Inventors: Wei Chen, David J. Loury, Longcheng Wang
  • Inhibitors of Bruton'S tyrosine kinase
    Patent number: 9079908
    Abstract: Described herein are irreversible kinase inhibitor compounds exemplified by the following structure Formula (B2): methods for synthesizing such irreversible inhibitors, and methods for using such irreversible inhibitors in the treatment of a B cell proliferative disorder or a mast cell proliferative disorder.
    Type: Grant
    Filed: July 6, 2012
    Date of Patent: July 14, 2015
    Assignee: Pharmacyclics, Inc.
    Inventors: Lee Honigberg, Erik J. Verner, Joseph J. Buggy, David J. Loury, Wei Chen
  • Pyrrolopyrimidine compounds as kinase inhibitors
    Patent number: 9062058
    Abstract: Disclosed herein are compounds exemplified by the following structure Formula (I) that form covalent bonds with Bruton's tyrosine kinase (Btk). Also disclosed are pharmaceutical compositions that include the compounds of Formula (I). Methods of using the Btk inhibitors exemplified by the structure of Formula (I) are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
    Type: Grant
    Filed: November 15, 2013
    Date of Patent: June 23, 2015
    Assignee: PHARMACYCLICS, INC.
    Inventors: Wei Chen, David J. Loury, Longcheng Wang
  • FORMULATIONS OF HISTONE DEACETYLASE INHIBITOR AND USES THEROF
    Publication number: 20150164854
    Abstract: Dosing regimens, methods of treatment, controlled release formulations, and combination therapies that include an HDAC inhibitor, or a pharmaceutically acceptable salt thereof, are described.
    Type: Application
    Filed: February 11, 2015
    Publication date: June 18, 2015
    Inventors: David J. LOURY, Joseph J. BUGGY, Tarak D. MODY, Erik J. VERNER, Norbert PURRO, Sriram Balasubramanian